Seaport Therapeutics, Inc. Stock: price and insider trades · United States
1 insider bought €89k of shares over the last 90 days, the latest by Torres Denice, filed 04 Nov 2026.
Seaport Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Seaport Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. In the past year (4 November 2025 to 4 November 2026), 2 filings came from 2 insiders.
Only purchases show up on the open market, 2 purchases in all worth €295k, filed by 2 insiders. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The largest single trade was a purchase of €206k by Hombach Robert J., published on 24 June 2026. Those buying include 2 senior executives.
The last insider purchase was made public on 4 November 2026, 4 days ago.
For context, the typical company on the same exchange (median of 3,182 companies) published 24 filings over the same period, against 2 filings here. Over the whole record (from 2026), the tally stands at 2 purchases and no sales.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- +10.0%Entry US$19.36 · Close at T+90 US$21.29
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Seaport Therapeutics, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$37.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 5,000 shares@ US$19.865Common StockSEC:0001193125-26-446216:0Canonical exit: 1 Feb 2027 (T+90)
- 13,000 shares@ US$18.136100.0% of flowCommon StockSEC:0001193125-26-280175:0Canonical exit: 20 Sept 2026 (T+90)
2 of 2 declarations
About Seaport Therapeutics, Inc.
Seaport Therapeutics, Inc. is a company focused on developing innovative therapies. It specializes in the research and commercialization of treatments for serious diseases.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
